Metabolic screening for patients with second-generation antipsychotic medication: A population-based study from 2004 to 2016

Patients with severe mental disorders have excess mortality due to preventable physical diseases, especially cardiovascular disease (Crump et al., 2013). One of the major risk factors for cardiovascular diseases is metabolic syndrome (Kaur, 2014), yet it has been reported that the prevalence for patients to develop metabolic syndrome doubles that of the general population (Riordan et al., 2011). A link between second-generation antipsychotic medications and the increased risk for both metabolic and cardiovascular abnormalities has been proposed (De Hert et al., 2012).

Source: Schizophrenia Research - February 22, 2018 Category: Psychiatry Authors: Edwin H.M. Lee, Christy L.M. Hui, Eunice Y.L. Law, P.Y. Chan, W.C. Chang, Sherry K.W. Chan, Eric Y.H. Chen Tags: Letter to the Editor Source Type: research